James J Lee1,2, Jan H Beumer3,4,5, Edward Chu3,4. 1. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, 5150 Centre Ave., Fifth Floor, Pittsburgh, PA, 15232, USA. leejj@upmc.edu. 2. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. leejj@upmc.edu. 3. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, 5150 Centre Ave., Fifth Floor, Pittsburgh, PA, 15232, USA. 4. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 5. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
PURPOSE: For over 50 years, 5-FU has played a critical role in the systemic chemotherapy of cancer patients. 5-FU serves as the main backbone of combination chemotherapy for patients with colorectal cancer in both the adjuvant and metastatic disease settings. Herein, we review the current status of 5-FU therapeutic drug monitoring (TDM) and discuss its potential role in the clinical practice setting. METHOD: PubMed and abstracts from the American Society of Clinical Oncology were searched up through September 2015 for clinical data relating to 5-FU TDM. RESULTS: 5-FU dosing has been typically determined by using body surface area (BSA). However, it is now well established that BSA-based 5-FU dosing is correlated with a wide variation of 5-FU systemic exposure. Pharmacokinetic (PK) studies of 5-FU systemic exposure have shown a wide range of interpatient variation of 5-FU plasma drug levels. Over the past 30 years, increasing efforts have been placed on optimizing 5-FU dosing with the main goals of increasing antitumor efficacy while reducing drug-associated toxicity. There is growing evidence to show that 5-FU dosing based on plasma 5-FU drug level is feasible and that 5-FU TDM can improve clinical outcomes by improving efficacy of 5-FU-based combination regimens and reducing toxicities. CONCLUSION: Dose adjustment of 5-FU is feasible, and PK-based dosing can significantly improve clinical outcomes by reducing toxicities and improving efficacy.
PURPOSE: For over 50 years, 5-FU has played a critical role in the systemic chemotherapy of cancerpatients. 5-FU serves as the main backbone of combination chemotherapy for patients with colorectal cancer in both the adjuvant and metastatic disease settings. Herein, we review the current status of 5-FU therapeutic drug monitoring (TDM) and discuss its potential role in the clinical practice setting. METHOD: PubMed and abstracts from the American Society of Clinical Oncology were searched up through September 2015 for clinical data relating to 5-FU TDM. RESULTS:5-FU dosing has been typically determined by using body surface area (BSA). However, it is now well established that BSA-based 5-FU dosing is correlated with a wide variation of 5-FU systemic exposure. Pharmacokinetic (PK) studies of 5-FU systemic exposure have shown a wide range of interpatient variation of 5-FU plasma drug levels. Over the past 30 years, increasing efforts have been placed on optimizing 5-FU dosing with the main goals of increasing antitumor efficacy while reducing drug-associated toxicity. There is growing evidence to show that 5-FU dosing based on plasma 5-FU drug level is feasible and that 5-FU TDM can improve clinical outcomes by improving efficacy of 5-FU-based combination regimens and reducing toxicities. CONCLUSION: Dose adjustment of 5-FU is feasible, and PK-based dosing can significantly improve clinical outcomes by reducing toxicities and improving efficacy.
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: C J van Groeningen; H M Pinedo; J Heddes; R M Kok; A P de Jong; E Wattel; G J Peters; J Lankelma Journal: Cancer Res Date: 1988-12-01 Impact factor: 12.701
Authors: O Capitain; M Boisdron-Celle; A-L Poirier; S Abadie-Lacourtoisie; A Morel; E Gamelin Journal: Pharmacogenomics J Date: 2007-08-14 Impact factor: 3.550
Authors: Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger Journal: Clin Pharmacol Ther Date: 2018-09-11 Impact factor: 6.875
Authors: Wael A Mahdi; Afzal Hussain; Mohd Ramzan; Abdul Faruk; Sarah I Bukhari; Abhimanyu Dev Journal: AAPS PharmSciTech Date: 2021-02-03 Impact factor: 3.246
Authors: A T Sougiannis; B N VanderVeen; R T Enos; K T Velazquez; J E Bader; M Carson; I Chatzistamou; M Walla; M M Pena; J L Kubinak; M Nagarkatti; J A Carson; E A Murphy Journal: Brain Behav Immun Date: 2019-02-23 Impact factor: 19.227